Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18923463 | POLYNUCLEOTIDES ENCODING PARAOXONASE FUSION POLYPEPTIDES | October 2024 | December 2024 | Allow | 1 | 0 | 0 | No | No |
| 18456262 | ANTI-SEZ6 ANTIBODY DRUG CONJUGATES | August 2023 | July 2024 | Allow | 10 | 2 | 0 | No | No |
| 18546413 | PARAOXONASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | August 2023 | July 2024 | Allow | 12 | 1 | 1 | No | No |
| 18348948 | ENGINEERED NUCLEASES, COMPOSITIONS, AND METHODS OF USE THEREOF | July 2023 | March 2024 | Allow | 9 | 1 | 1 | No | No |
| 18185805 | COMPOSITION AND METHOD OF USE RECOMBINANT FUSION PROTEIN TO GENERATE CAR-IMMUNE CELLS | March 2023 | February 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18043723 | USE OF VITELLOGENIN FOR DEFINING AND TESTING NOVEL IMMUNOGENS IN INSECTS | March 2023 | July 2024 | Allow | 17 | 1 | 1 | No | No |
| 18054018 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | November 2022 | June 2025 | Abandon | 32 | 3 | 1 | No | No |
| 17817754 | HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODIES | August 2022 | October 2023 | Allow | 15 | 0 | 1 | Yes | No |
| 17877083 | PHOSPHINE-MEDIATED AMINE-AZIDE COUPLING IN IONIC LIQUID FOR BIOCONJUGATION REACTIONS | July 2022 | June 2024 | Abandon | 22 | 1 | 1 | Yes | No |
| 17874711 | ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING CT45 | July 2022 | September 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17854735 | MULTIVALENT ANTI-SARS-COV-2 NANOBODIES | June 2022 | April 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17836517 | ANTIBODIES TARGETING AN AMPHIREGULIN-DERIVED CELL SURFACE NEO-EPITOPE | June 2022 | March 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 17836480 | COMBINATION MCL-1 INHIBITORS WITH ANTI-BODY DRUG CONJUGATES | June 2022 | November 2023 | Allow | 17 | 1 | 0 | No | No |
| 17832093 | DOSING OF A BISPECIFIC ANTIBODY THAT BINDS CD20 AND CD3 | June 2022 | January 2024 | Allow | 19 | 1 | 0 | No | No |
| 17829671 | TUMOR CELL VACCINES | June 2022 | January 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17828740 | ANTI-NKG2A ANTIBODIES AND COMPOSITIONS | May 2022 | February 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 17727628 | COMPOSITIONS AND METHODS FOR TREATMENT OF INVASIVE CANCERS | April 2022 | April 2024 | Allow | 24 | 3 | 0 | Yes | No |
| 17690968 | IMMUNE CELL FUNCTION | March 2022 | April 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17582355 | METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY | January 2022 | January 2024 | Allow | 24 | 1 | 0 | No | No |
| 17554557 | Rocky Mountain Spotted Fever Detection and Treatment | December 2021 | October 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17517535 | COMPOSITIONS AND METHODS EMPLOYING ADENOSINE DEAMINASE-1 (ADA-1) AS AN ADJUVANT | November 2021 | April 2024 | Allow | 29 | 1 | 1 | No | No |
| 17516601 | SAP FC FUSION PROTEINS AND METHODS OF USE | November 2021 | October 2024 | Allow | 35 | 2 | 1 | No | No |
| 17516259 | BREAST CANCER TUMOR CELL VACCINES | November 2021 | December 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17516203 | COLORECTAL CANCER TUMOR CELL VACCINES | November 2021 | December 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17512071 | FLOW CYTOMETRIC METHOD FOR CHARACTERIZATION OF T-CELL IMPURITIES | October 2021 | June 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17499444 | BIOMARKERS FOR DETERMINING SURVIVAL AND THERAPEUTIC RESPONSE IN CERVICAL CANCER | October 2021 | March 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17295225 | OX40 ANTIBODY, PREPARATION METHOD THEREOF AND USE THEREOF | September 2021 | May 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17433780 | FORMULATION COMPRISING ANTI-CD47 ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF | August 2021 | June 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17409462 | SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS | August 2021 | October 2024 | Allow | 38 | 1 | 0 | No | No |
| 17427301 | ANTI-FGF19 ANTIBODIES | July 2021 | June 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17427117 | SIGNALING PLATFORMS FOR CHIMERIC ANTIGEN RECEPTOR T CELLS | July 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17426723 | BELANTAMAB MAFODOTIN IN COMBINATION WITH PEMBROLIZUMAB FOR TREATING CANCER | July 2021 | April 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17420987 | ANTI-TIGIT ANTIBODIES | July 2021 | January 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17413456 | METHOD OF TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES USING B CELLS | June 2021 | April 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17311619 | HUMAN ANTI-ANTXR CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | June 2021 | March 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17295896 | AN ANTI-B7-H3 ANTIBODY | May 2021 | September 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17295603 | ANTIBODY AND USE THEREOF | May 2021 | January 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17295773 | ANTI-TNFR2 ANTIBODY AND USE THEREOF | May 2021 | January 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17295394 | ANTI-PD-L1/VEGF BIFUNCTIONAL ANTIBODY AND USE THEREOF | May 2021 | December 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17320891 | ALS Treatment Using Induced Regulatory T (iTREG) Cells | May 2021 | September 2024 | Allow | 40 | 1 | 1 | No | No |
| 17320125 | CD25 ANTIBODIES | May 2021 | October 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17289058 | DC-SIGN ANTIBODY DRUG CONJUGATES | April 2021 | January 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17285303 | METHODS AND COMPOSITIONS FOR TREATING TAUOPATHIES | April 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17280726 | DUAL TARGETING ANTIGEN BINDING MOLECULE | March 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17280537 | METHODS OF TREATING INFLAMMATION | March 2021 | April 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17274858 | ADMINISTRATION OF AN ANTI-C5 AGENT FOR TREATMENT OF HEPATIC INJURY OR FAILURE | March 2021 | September 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17274512 | METHOD OF PROVIDING SAFE ADMINISTRATION OF AN ANTI-CD154 ANTIBODY | March 2021 | September 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17272027 | MONOCLONAL ANTIBODY 14F5F6 OR FRAGMENT THEREOF, THAT SPECIFICALLY RECOGNIZES HERPES SIMPLEX VIRUS 1 AND 2 | February 2021 | November 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17176841 | METHODS FOR ACTIVATING T CELLS USING AN INDUCIBLE CHIMERIC POLYPEPTIDE | February 2021 | August 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17267637 | ANTI-HUMAN CLAUDIN 18.2 MONOCLONAL ANTIBODY AND APPLICATION THEREOF | February 2021 | September 2024 | Allow | 43 | 1 | 1 | No | No |
| 17164197 | COMPOSITIONS AND METHODS FOR PROVIDING CHEMOPROTECTIVE EFFECTS | February 2021 | April 2025 | Allow | 50 | 4 | 0 | No | No |
| 17262351 | NOVEL CLDN 18.2-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF | January 2021 | March 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17154678 | METHOD FOR PURIFYING ANTIBODIES | January 2021 | March 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17259910 | Use Of Liposomes To Deliver A Protein And A Gene Encoding The Protein To A Live Cell | January 2021 | January 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17259634 | MESOTHELIN AND CD137 BINDING MOLECULES | January 2021 | January 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17259642 | ANTIBODY MOLECULES | January 2021 | October 2024 | Allow | 45 | 1 | 1 | No | No |
| 17259051 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC-ANTIGEN BINDING DOMAIN CONSTRUCTS | January 2021 | June 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17250353 | EFFICIENTLY EXPRESSED EGFR AND PD-L1 BISPECIFIC BINDING PROTEINS | January 2021 | August 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17051293 | Biosensors for Measuring Metastatic Potential and Chemoresistance of Single Cancer Cells | October 2020 | May 2025 | Allow | 54 | 3 | 1 | Yes | No |
| 17047134 | LYSATES OF RECOMBINANT YEAST FOR INDUCING CELLULAR IMMUNE RESPONSES | October 2020 | September 2024 | Allow | 47 | 1 | 1 | No | No |
| 17046169 | METHODS OF TREATMENT FOR CANDIDA AURIS INFECTIONS | October 2020 | February 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 17042032 | METHODS OF TREATING GLIOBLASTOMAS | September 2020 | April 2024 | Allow | 43 | 1 | 0 | Yes | No |
| 17027856 | General Sequence Of Chimeric Antigen Receptor, Chimeric Antigen Receptor And An Application Thereof | September 2020 | January 2024 | Allow | 39 | 0 | 1 | Yes | No |
| 16976040 | COMPOSITIONS AND METHODS FOR CELLULAR IMMUNOTHERAPY | August 2020 | April 2025 | Abandon | 55 | 1 | 1 | No | No |
| 16999123 | METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES | August 2020 | November 2024 | Abandon | 51 | 1 | 1 | No | No |
| 16966339 | CONSTRUCTION AND METHODS OF USE OF A BARCODED AND GENE EDITED DNA LIBRARY | July 2020 | July 2024 | Allow | 47 | 0 | 1 | Yes | No |
| 16919236 | USE OF CAPRYLIC ACID PRECIPITATION FOR PROTEIN PURIFICATION | July 2020 | October 2024 | Abandon | 51 | 1 | 1 | No | No |
| 16955684 | FUSION PROTEINS | June 2020 | April 2024 | Abandon | 46 | 3 | 1 | No | No |
| 16768617 | BINDING PROTEINS SPECIFIC FOR 5T4 AND USES THEREOF | May 2020 | May 2024 | Abandon | 47 | 0 | 1 | No | No |
| 16881102 | USE OF ALKALINE WASHES DURING CHROMATOGRAPHY TO REMOVE IMPURITIES | May 2020 | July 2024 | Allow | 50 | 2 | 0 | No | No |
| 16754877 | NETRIN G1 AS A BIOMARKER FOR ENHANCING TUMOR TREATMENT EFFICACY | April 2020 | May 2024 | Allow | 49 | 4 | 1 | Yes | No |
| 16842864 | Methods of Controlling the Formation of Disulfide Bonds in Protein Solutions | April 2020 | October 2024 | Abandon | 54 | 1 | 1 | No | No |
| 16650415 | METHOD FOR CONFIRMING PRDM14 EXPRESSION | March 2020 | March 2024 | Abandon | 48 | 0 | 1 | No | No |
| 16644544 | METHODS AND DEVICES FOR DETECTING BIOMARKERS ASSOCIATED WITH PREECLAMPSIA | March 2020 | February 2024 | Abandon | 48 | 0 | 1 | No | No |
| 15680080 | IMMUNOCONJUGATES FOR SPECIFIC INDUCTION OF T CELL CYTOTOXICITY AGAINST A TARGET CELL | August 2017 | May 2024 | Abandon | 60 | 7 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner STONEBRAKER, ALYSSA RAE works in Art Unit 1642 and has examined 74 patent applications in our dataset. With an allowance rate of 59.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner STONEBRAKER, ALYSSA RAE's allowance rate of 59.5% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by STONEBRAKER, ALYSSA RAE receive 1.27 office actions before reaching final disposition. This places the examiner in the 24% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by STONEBRAKER, ALYSSA RAE is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +61.0% benefit to allowance rate for applications examined by STONEBRAKER, ALYSSA RAE. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 66.7% of cases where such amendments are filed. This entry rate is in the 88% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 62.5% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.